Literature DB >> 20401487

[Osteoporosis diagnosis and therapy according to the 2010 guidelines].

J Braun1, J Pfeilschifter.   

Abstract

Osteoporotic fractures are a frequent cause of disability and loss of quality of life in old age. Maintaining muscle function and balance, a daily calcium intake of 1000 mg, sufficient vitamin D and prudent use of drugs associated with falls and osteoporosis are key components to fracture prevention. The German guideline recommends that a specific long-term osteoporosis medication be initiated in individuals with a 30% 10-year risk for hip fractures and vertebral fractures.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20401487     DOI: 10.1007/s00393-010-0623-3

Source DB:  PubMed          Journal:  Z Rheumatol        ISSN: 0340-1855            Impact factor:   1.372


  21 in total

1.  Can you diagnose for vertebral fracture correctly by plain X-ray?

Authors:  Z Ito; A Harada; Y Matsui; M Takemura; N Wakao; T Suzuki; T Nihashi; S Kawatsu; H Shimokata; N Ishiguro
Journal:  Osteoporos Int       Date:  2006-08-18       Impact factor: 4.507

Review 2.  Consensus development conference: diagnosis, prophylaxis, and treatment of osteoporosis.

Authors: 
Journal:  Am J Med       Date:  1993-06       Impact factor: 4.965

3.  A meta-analysis of previous fracture and subsequent fracture risk.

Authors:  J A Kanis; O Johnell; C De Laet; H Johansson; A Oden; P Delmas; J Eisman; S Fujiwara; P Garnero; H Kroger; E V McCloskey; D Mellstrom; L J Melton; H Pols; J Reeve; A Silman; A Tenenhouse
Journal:  Bone       Date:  2004-08       Impact factor: 4.398

Review 4.  Vitamin D deficiency: a worldwide problem with health consequences.

Authors:  Michael F Holick; Tai C Chen
Journal:  Am J Clin Nutr       Date:  2008-04       Impact factor: 7.045

5.  Risk of hip fracture after bisphosphonate discontinuation: implications for a drug holiday.

Authors:  J R Curtis; A O Westfall; H Cheng; E Delzell; K G Saag
Journal:  Osteoporos Int       Date:  2008-05-16       Impact factor: 4.507

6.  Fracture outcomes related to persistence and compliance with oral bisphosphonates.

Authors:  Arlene M Gallagher; Stephan Rietbrock; Melvin Olson; Tjeerd P van Staa
Journal:  J Bone Miner Res       Date:  2008-10       Impact factor: 6.741

7.  Denosumab in men receiving androgen-deprivation therapy for prostate cancer.

Authors:  Matthew R Smith; Blair Egerdie; Narciso Hernández Toriz; Robert Feldman; Teuvo L J Tammela; Fred Saad; Jiri Heracek; Maciej Szwedowski; Chunlei Ke; Amy Kupic; Benjamin Z Leder; Carsten Goessl
Journal:  N Engl J Med       Date:  2009-08-11       Impact factor: 91.245

Review 8.  Is a change in bone mineral density a sensitive and specific surrogate of anti-fracture efficacy?

Authors:  E Seeman
Journal:  Bone       Date:  2007-06-26       Impact factor: 4.398

9.  Risk for fracture in women with low serum levels of thyroid-stimulating hormone.

Authors:  D C Bauer; B Ettinger; M C Nevitt; K L Stone
Journal:  Ann Intern Med       Date:  2001-04-03       Impact factor: 25.391

10.  Ten-year fracture probability identifies women who will benefit from clodronate therapy--additional results from a double-blind, placebo-controlled randomised study.

Authors:  E V McCloskey; H Johansson; A Oden; S Vasireddy; K Kayan; K Pande; T Jalava; J A Kanis
Journal:  Osteoporos Int       Date:  2008-11-11       Impact factor: 4.507

View more
  3 in total

Review 1.  Osteoporosis, frailty and fracture: implications for case finding and therapy.

Authors:  Joop P van den Bergh; Tineke A van Geel; Piet P Geusens
Journal:  Nat Rev Rheumatol       Date:  2012-01-17       Impact factor: 20.543

2.  [Managing comorbidities of inflammatory rheumatic diseases].

Authors:  K de Groot; E Märker-Hermann
Journal:  Internist (Berl)       Date:  2011-06       Impact factor: 0.743

Review 3.  A reappraisal of generic bisphosphonates in osteoporosis.

Authors:  J A Kanis; J-Y Reginster; J-M Kaufman; J-D Ringe; J D Adachi; M Hiligsmann; R Rizzoli; C Cooper
Journal:  Osteoporos Int       Date:  2011-09-28       Impact factor: 4.507

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.